Literature DB >> 32289587

Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of Group A Streptococcus synthetic oligorhamnans.

Olimpia Pitirollo1, Francesca Micoli2, Francesca Necchi2, Francesca Mancini2, Martina Carducci2, Roberto Adamo3, Claudio Evangelisti4, Laura Morelli5, Laura Polito6, Luigi Lay7.   

Abstract

The development of novel delivery systems capable of enhancing the antibody binding affinity and immunoactivity of short length saccharide antigens is at the forefront of modern medicine. In this regard, gold nanoparticles (AuNPs) raised great interest as promising nano-vaccine platform, as they do not interfere with the desired immune response and their surface can be easily functionalized, enabling the antigen multivalent presentation. In addition, the nanoparticles morphology can have a great impact on their biological properties. Gram-positive Group A Streptococcus (GAS) is a bacterium responsible for many infections and represents a priority healthcare concern, but a universal vaccine is still unavailable. Since all the GAS strains have a cell wall characterized by a common polyrhamnose backbone, this can be employed as alternative antigen to develop an anti-GAS vaccine. Herein, we present the synthesis of two oligorhamnoside fragments and their corresponding oligorhamnoside-AuNPs, designed with two different morphologies. By competitive ELISA we assessed that both symmetric and anisotropic oligorhamnan nanoparticles inhibit the binding of specific polyclonal serum much better than the unconjugated oligosaccharides.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glycoconjugate vaccine; Gold nanoparticles; Group A Streptococcus; Synthetic oligosaccharides

Mesh:

Substances:

Year:  2020        PMID: 32289587     DOI: 10.1016/j.bioorg.2020.103815

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  6 in total

1.  Immunobiology of the Classical Lancefield Group A Streptococcal Carbohydrate Antigen.

Authors:  Nina J Gao; Ervin Rodas Lima; Victor Nizet
Journal:  Infect Immun       Date:  2021-09-20       Impact factor: 3.441

2.  Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development.

Authors:  Guirong Wang; Jielin Zhao; Yisheng Zhao; Subo Wang; Shaojie Feng; Guofeng Gu
Journal:  Vaccines (Basel)       Date:  2021-02-09

3.  Non-Native Amino Acid Click Chemistry-Based Technology for Site-Specific Polysaccharide Conjugation to a Bacterial Protein Serving as Both Carrier and Vaccine Antigen.

Authors:  Neeraj Kapoor; Satoshi Uchiyama; Lucy Pill; Leslie Bautista; Angie Sedra; Lu Yin; Maritoni Regan; Ellen Chu; Taylor Rabara; Melissa Wong; Peter Davey; Jeff Fairman; Victor Nizet
Journal:  ACS Omega       Date:  2022-07-11

4.  GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A Streptococcus.

Authors:  Elena Palmieri; Zoltán Kis; James Ozanne; Roberta Di Benedetto; Beatrice Ricchetti; Luisa Massai; Martina Carducci; Davide Oldrini; Gianmarco Gasperini; Maria Grazia Aruta; Omar Rossi; Cleo Kontoravdi; Nilay Shah; Fatme Mawas; Francesca Micoli
Journal:  Vaccines (Basel)       Date:  2022-06-28

5.  Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus.

Authors:  Roberta Di Benedetto; Francesca Mancini; Martina Carducci; Gianmarco Gasperini; Danilo Gomes Moriel; Allan Saul; Francesca Necchi; Rino Rappuoli; Francesca Micoli
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 6.  Glyconanoparticles as tools to prevent antimicrobial resistance.

Authors:  Laura Morelli; Laura Polito; Barbara Richichi; Federica Compostella
Journal:  Glycoconj J       Date:  2021-03-17       Impact factor: 2.916

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.